251 related articles for article (PubMed ID: 26596901)
1. Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4.
Allen BK; Mehta S; Ember SW; Schonbrunn E; Ayad N; Schürer SC
Sci Rep; 2015 Nov; 5():16924. PubMed ID: 26596901
[TBL] [Abstract][Full Text] [Related]
2. In silico study directed towards identification of novel high-affinity inhibitors targeting an oncogenic protein: BRD4-BD1.
Tumdam R; Kumar A; Subbarao N; Balaji BS
SAR QSAR Environ Res; 2018 Dec; 29(12):975-996. PubMed ID: 30411639
[TBL] [Abstract][Full Text] [Related]
3. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
4. Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains.
Wang J; Erazo T; Ferguson FM; Buckley DL; Gomez N; Muñoz-Guardiola P; Diéguez-Martínez N; Deng X; Hao M; Massefski W; Fedorov O; Offei-Addo NK; Park PM; Dai L; DiBona A; Becht K; Kim ND; McKeown MR; Roberts JM; Zhang J; Sim T; Alessi DR; Bradner JE; Lizcano JM; Blacklow SC; Qi J; Xu X; Gray NS
ACS Chem Biol; 2018 Sep; 13(9):2438-2448. PubMed ID: 30102854
[TBL] [Abstract][Full Text] [Related]
5. Investigation of novel ligand targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery: complete pharmacophore approach.
Shanmugam V; Muthukrishnan S
J Biomol Struct Dyn; 2023; 41(23):14524-14539. PubMed ID: 36841551
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.
Xue X; Zhang Y; Liu Z; Song M; Xing Y; Xiang Q; Wang Z; Tu Z; Zhou Y; Ding K; Xu Y
J Med Chem; 2016 Feb; 59(4):1565-79. PubMed ID: 26731490
[TBL] [Abstract][Full Text] [Related]
7. Machine-Learning-Assisted Approach for Discovering Novel Inhibitors Targeting Bromodomain-Containing Protein 4.
Xing J; Lu W; Liu R; Wang Y; Xie Y; Zhang H; Shi Z; Jiang H; Liu YC; Chen K; Jiang H; Luo C; Zheng M
J Chem Inf Model; 2017 Jul; 57(7):1677-1690. PubMed ID: 28636361
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a Small-Molecule Bromodomain-Containing Protein 4 (BRD4) Inhibitor That Induces AMP-Activated Protein Kinase-Modulated Autophagy-Associated Cell Death in Breast Cancer.
Ouyang L; Zhang L; Liu J; Fu L; Yao D; Zhao Y; Zhang S; Wang G; He G; Liu B
J Med Chem; 2017 Dec; 60(24):9990-10012. PubMed ID: 29172540
[TBL] [Abstract][Full Text] [Related]
10. Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis.
Andrews FH; Singh AR; Joshi S; Smith CA; Morales GA; Garlich JR; Durden DL; Kutateladze TG
Proc Natl Acad Sci U S A; 2017 Feb; 114(7):E1072-E1080. PubMed ID: 28137841
[No Abstract] [Full Text] [Related]
11. Small-Molecule Targeting of BET Proteins in Cancer.
French CA
Adv Cancer Res; 2016; 131():21-58. PubMed ID: 27451123
[TBL] [Abstract][Full Text] [Related]
12. Targeting BET bromodomains for cancer treatment.
Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B
Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel BRD4 inhibitors by high-throughput screening, crystallography, and cell-based assays.
Sun Z; Zhang H; Chen Z; Xie Y; Jiang H; Chen L; Ding H; Zhang Y; Jiang H; Zheng M; Luo C
Bioorg Med Chem Lett; 2017 May; 27(9):2003-2009. PubMed ID: 28347667
[TBL] [Abstract][Full Text] [Related]
14. Importance of a crystalline water network in docking-based virtual screening: a case study of BRD4.
Zhong H; Wang Z; Wang X; Liu H; Li D; Liu H; Yao X; Hou T
Phys Chem Chem Phys; 2019 Dec; 21(45):25276-25289. PubMed ID: 31701109
[TBL] [Abstract][Full Text] [Related]
15. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors.
Ember SW; Zhu JY; Olesen SH; Martin MP; Becker A; Berndt N; Georg GI; Schönbrunn E
ACS Chem Biol; 2014 May; 9(5):1160-71. PubMed ID: 24568369
[TBL] [Abstract][Full Text] [Related]
16. Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.
Stratikopoulos EE; Dendy M; Szabolcs M; Khaykin AJ; Lefebvre C; Zhou MM; Parsons R
Cancer Cell; 2015 Jun; 27(6):837-51. PubMed ID: 26058079
[TBL] [Abstract][Full Text] [Related]
17. Molecular docking and dynamics simulation study of flavonoids as BET bromodomain inhibitors.
Raj U; Kumar H; Varadwaj PK
J Biomol Struct Dyn; 2017 Aug; 35(11):2351-2362. PubMed ID: 27494802
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of dihydroquinoxalinone derivatives as BRD4 inhibitors.
Yang Y; Zhao L; Xu B; Yang L; Zhang J; Zhang H; Zhou J
Bioorg Chem; 2016 Oct; 68():236-44. PubMed ID: 27580186
[TBL] [Abstract][Full Text] [Related]
19. Structure-based virtual screening of novel, high-affinity BRD4 inhibitors.
Muvva C; Singam ER; Raman SS; Subramanian V
Mol Biosyst; 2014 Jul; 10(9):2384-97. PubMed ID: 24976024
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel [1,2,4]triazolo[4,3-a]quinoxaline aminophenyl derivatives as BET inhibitors for cancer treatment.
Ali I; Lee J; Go A; Choi G; Lee K
Bioorg Med Chem Lett; 2017 Oct; 27(20):4606-4613. PubMed ID: 28939121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
